Recently, mutations in the calreticulin (CALR) gene, which encodes the calreticulin protein, were found in 50–80% of ET and PMF patients, all of whom lacked JAK2 and MPL mutations [9, 10]. Here, JAK2 is linked to essential thrombocythemia.